+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Theranostic Approach for Pancreatic Cancer

  • ID: 4806656
  • Book
  • 410 Pages
  • Elsevier Science and Technology
1 of 3
Theranostic Approach for Pancreatic Cancer modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property through introducing new strategies and drugs for tackling the disease. It brings information about ongoing research as well as clinical data about pancreatic cancer and provides detailed descriptions about diagnostic and therapeutic options for easy understanding. The book discusses several topics related to pancreatic cancer, such as stem cells, drug resistance and pancreatic tumor microenvironment, the latest developments in chemotherapy for metastatic cancer and chemoprevention, and epigenome as a therapeutic strategy.

Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, oncologists, and several members of the biomedical field who need to understand more about the diagnosis and treatment of pancreatic cancer.

- Provides information on the roadblocks of chemotherapy in patients with newly diagnosed and metastatic pancreatic cancer<- Discusses treatment options available currently and prospective options for the future- Focuses especially on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways as already tested types of treatment

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Note: Product cover images may vary from those shown
2 of 3
1. Biology, pathophysiology and epidemiology of pancreatic cancer
2. Diagnosis of pancreatic cancer
3. Current knowledge on drug resistance and therapeutic approaches to eliminate pancreatic cancer stem cells
4. Drug resistance and microenvironment in pancreatic cancer
5. The role of tumor microenvironment in the metastasis of pancreatic cancer and immunotherapy
6. Latest developments in chemotherapy for metastatic pancreatic cancer
7. Genetic manipulations with chemotherapy in pancreatic cancer
8. Genetic predisposition for pancreatic cancer
9. Pancreatic cancer resistance to chemotherapy: Resensitization strategies using resveratrol
10. Anti-cancer activity of a small molecule, tolfenamic acid: An emphasis on pancreatic cancer
11. Targeting the epigenome as a therapeutic strategy for pancreatic tumors
Non-coding RNAs and chromatin remodelers
12. Pancreatic cancer chemoprevention: A review on molecular pathways involved in carcinogenesis and targeting with terpenoids, a new potential anti-tumor drugs
13. Meta-analysis on MTHFR polymorphisms and pancreatic cancer susceptibility
14. Therapeutic vaccines for pancreatic cancer
15. Epidermal growth factor receptor role in pancreatic cancer
16. Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Nagaraju, Ganji Purnachandra
Dr. Nagaraju GP is a faculty member in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. Dr. Nagaraju received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju's research focuses on translational projects related to gastrointestinal malignancies. He has published over 70 research papers in highly reputed International journals and has presented more than 50 abstracts at various national and international conferences. Dr, Nagaraju is author and editor of several published books including 1. Role of Tyrosine Kinases in Gastrointestinal Malignancies, 2. Role of Transcription Factors in Gastrointestinal Malignancies and 3. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju is an associate member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).
Ahmad, Sarfraz
Dr. Ahmad is Director of Clinical Research at Gynecologic Oncology Department of AdventHealth (formerly Florida Hospital) Cancer Institute (FHCI), Orlando, FL, USA. He earned his Ph.D. degree in Biochemistry from North-Eastern Hill University, Shillong. Before joining FHCI in 2002, he spent 10-years in research and teaching at Loyola University of Chicago and University of Illinois at Chicago's Division of Hematology/Oncology, College of Medicine. He has trained several fellows, residents, medical students, and graduate/undergraduate students during their scholarly research projects. He is also Professor of Medical Education at University of Central Florida College of Medicine and Professor of Clinical Sciences at Florida State University College of Medicine, Orlando, USA. Dr. Ahmad's current research focus is on the analysis of clinico-pathologic and surgical outcomes of oncology patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic / hematologic disorders. His investigations are also aimed towards the evaluation of novel treatment options (chemo/cellular/immuno-therapies) for better management of hemato-oncologic patients. His past research interests focused on the anticoagulant, antithrombin, antiplatelet, and thrombolytic drug development for the management of hematologic and cardiovascular patients. In these various areas of biomedical research, Dr. Ahmad has published nearly 200 peer-reviewed scholarly research articles and book chapters, and nearly 400 scientific abstracts, which are extensively cited globally. He is a reviewer and has editorial responsibilities for several biomedical journals/books; and has received several competitive research grants and national/international awards for his research accomplishments/contributions.
Note: Product cover images may vary from those shown
Adroll
adroll